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Abstract
Background: Management guidelines of chronic obstructive pulmonary disease (COPD) are mainly based on
results of randomised controlled trials (RCTs), but some authors have suggested limited representativeness of
patients included in these trials. No previous studies have applied the full range of selection criteria to a broad
COPD patient population in a real-life setting.
Methods: We identified all RCTs of inhaled long-acting bronchodilator therapy, during 1999–2013, at ClinicalTrials.
gov and translated trial selection criteria into definitions compatible with electronic medical records. Eligibility was
calculated for each RCT by applying these criteria to a uniquely representative, well-characterised population of
patients with COPD from the Optimum Patient Care Research Database (OPCRD).
Results: Median eligibility of 36 893 patients with COPD for participation in 31 RCTs was 23 % (interquartile range
12–38). Two studies of olodaterol showed the highest eligibility of 55 and 58 %. Conversely, the lowest eligibility
was observed in two studies that required a history of exacerbations in the past year (3.5 and 3.9 %). For the
patient subgroup with modified Medical Research Council score ≥2, the overall median eligibility was 27 %.
Conclusions: By applying an extensive range of RCT selection criteria to a large, representative COPD patient
population, this study highlights that the interpretation of results from RCTs must take into account that
RCT participants are variably, but generally more representative of patients in the community than previously
believed.
Keywords: Randomised controlled trial, Real-life research, Chronic obstructive pulmonary disease, Long-acting
bronchodilator
Background
Chronic obstructive pulmonary disease (COPD) is a de-
bilitating disorder that has become a major public health
concern worldwide [1–3]. Guidelines for COPD manage-
ment and treatment are predominantly based on results
from double-blind, placebo-controlled, randomised con-
trolled trials (RCTs). Generally considered to be the
optimal study design to test the efficacy and safety of
medical interventions [2], RCTs are designed to answer
specific questions about treatments. This requires a
uniform and well-characterised patient population,
supervised care, careful monitoring, and control of fac-
tors that may confound or modify any potential effects
[4]. However, this stringent selection means that RCT
findings may be limited in the extent to which treatment
effects can be extrapolated to a broad general patient
population [4, 5]. For example, real-life patients with
COPD tend to be older than trial participants, either
because RCTs restrict the age range, or because they
exclude patients with comorbidities [6], and the latter
are sometimes excluded despite drug effectiveness being
influenced by comorbidities [7].
Treatment of most patients with COPD occurs under
very different conditions from RCTs, where a multitude
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of factors may influence the real-life effectiveness of
therapeutic options [8]. This gap between community
patients and RCTs leads to the so-called clinician’s fal-
lacy, in which an inaccurate view of the nature and
causes of a disease results from studying a small number
of cases in clinical trials [9]. The process of care in clin-
ical trials may also influence the assessment of treatment
efficacy: for example, guidelines for COPD management
recommend that patients with COPD are seen 1–2 times
a year [10], while many RCTs improve adherence
through much more frequent visits [11, 12]. Real-life
adherence to treatment is not only low, but also influ-
enced by side effects, which may in turn influence
patients’ response to medication [13–15].
Long-acting bronchodilators are currently one of the
first choices of maintenance medication for COPD ac-
cording to guidelines. These can be used alone, together
with other bronchodilators, or in combination with
inhaled corticosteroids (ICS) [2, 10]. However, little is
known about how representative participants of the
RCTs testing bronchodilators are of the general COPD
patient population. Despite this, there is a widespread
and frequently quoted assumption that over 90 % of
people treated for COPD would be ineligible to partici-
pate in RCTs [16–18]. To our knowledge, five studies
have addressed this question and have reported eligibility
ranges from 5 to 42 % [16, 19–22]. These studies were
all limited, either by considering a low number of
patients [16, 19, 21], by selecting patient populations
that are likely not representative of community pa-
tients with COPD [16, 21, 22], or by only considering
a limited range of selection criteria employed by
RCTs [16, 19–21]. Individual studies show that the
full range of criteria relevantly affect eligibility for
participation in RCTs. There is therefore a need to
combine the evidence provided by previous studies in
order to give the full picture of eligibility, as well as
to study any potential changes in trends [23].
A comprehensive assessment of the relevance of study
findings to general patient populations requires thor-
ough description of patient selection and clinical man-
agement [5]. The aim of this study was to determine the
proportion of the general UK patient population with
COPD that would be eligible for inclusion in recent
RCTs testing inhaled long-acting bronchodilators. The
objectives were; 1) to give an overview of inclusion and
exclusion criteria applied in relevant clinical trials, 2) to
describe the frequency of the characteristics and condi-
tions of these selection criteria in a general COPD pa-
tient population, identified from a large database of
anonymised medical records, and 3) to determine the
percentage of patients with COPD in the database who
would meet the eligibility criteria for RCTs of inhaled
long-acting bronchodilator therapy.
Methods
Selection of RCTs and study population
We selected RCTs investigating the effects of inhaled
long-acting bronchodilators in COPD from studies regis-
tered at https://clinicaltrials.gov/ through to 13 October
2014, using the criteria listed in Table 1. Briefly, eligible
RCTs were phase III or phase IV trials in which spirom-
etry parameters, COPD exacerbations, or COPD mortal-
ity were the primary efficacy outcome. For further
details on search terms, see the online supplement.
The population used to test the effects of selection cri-
teria was patients in the Optimum Patient Care Research
Database (OPCRD) [24], aged ≥40 years, with a con-
firmed diagnosis of COPD, as well as data on forced
expiratory volume in 1 s (FEV1), modified Medical
Research Council (mMRC) score [2] and full blood
counts (Table 1). The index date was defined as the date
of the last data extraction from the general practice.
Data source
The OPCRD is a quality-controlled, longitudinal,
respiratory-focused database that contains de-identified
Table 1 Criteria employed for selection of RCTs from
ClinicalTrials.gov, and patients from OPCRD
Selection criteria for RCTs
a. Recruiting patients with COPD
b. Phase III or Phase IV randomised, double-blind, placebo-controlled
trial, testing
i. Long-acting muscarinic antagonist (LAMA) OR
ii. Long-acting β-agonist (LABA) OR
iii. LAMA/LABA combination
c. Primary outcomes were
i. spirometry parameter(s) OR
ii. COPD exacerbations OR
iii. mortality
d. Duration of treatment was ≥24 weeks post-randomisation
e. Enrolled ≥100 patients with COPD
f. Medicine was tested at licensed dose
Selection of patients with COPD from the OPCRD database
a. Quality and Outcomes Framework (QOF) approved diagnostic code of
COPD, which includes the requirement for a post-bronchodilator
FEV1/FVC <0.70 [31]
b. Registered in OPCRD with data extracted from general practice at
least once after 1 January 2011. The index date was defined as the
date of the last data extraction
c. ≥1 year of data available prior to the index date to define RCT
inclusion/exclusion criteria
d. FEV1 and FVC recorded within 5 years of the index date
e. mMRC score recorded within 5 years of index date
f. Recorded valid blood eosinophil count ever
g. Age ≥40 years
Abbreviations: COPD chronic obstructive pulmonary disease, FEV1 forced
expiratory volume in 1 s, FVC forced vital capacity, mMRC score modified
Medical Research Council score [2]
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data from general practices across the UK [24]. The
database contains information about patient manage-
ment in primary and secondary care and combines elec-
tronic patient records with linked patient-reported data,
which are collected using disease-specific questionnaires.
Routine clinical data are extracted from general practice
management systems and include patient demographic
characteristics, comorbidities, exacerbation history,
mMRC score and current therapy. At the time of the
study, the OPCRD contained 44,376 patients with a
diagnostic Read code for COPD recorded who had data
extracted from practice at least once from January 2011
to January 2015. The database has been approved by the
Trent Multicentre Research Ethics Committee for clin-
ical research use (approval reference 10/H0405/3). The
study was approved by the Anonymised Data Ethics Pro-
tocols and Transparency committee, which is the inde-
pendent scientific advisory committee for the OPCRD,
and the study protocol was registered with the European
Network of Centres for Pharmacoepidemiology and
Pharmacovigilance (registration number ENCEPP/
SDPP/7727).
Methods of analysis
To identify and analyse the data, a stepwise method was
employed (see Additional file 1). Briefly, all inclusion
and exclusion criteria reported in eligible RCTs were
collected, and all published manuscripts and protocols
were checked for additional selection criteria. Eligibility
criteria were then divided into categories, which were
translated into definitions of criteria compatible with the
OPCRD database (Additional file 2: Tables S1 − S7).
These criteria were applied to the database patient popu-
lation with complete data on FEV1, full blood counts,
and mMRC score, and the results were reported as mean
(range) and/or median (interquartile range [IQR]). The
percentage of OPCRD patients eligible for inclusion in
each RCT was calculated for two reference populations:
the full eligible population of patients with COPD, and a
subpopulation with mMRC score ≥2, ie patients who
have symptoms of moderate dyspnea and comprise a
more specific target population for treatment with long-
acting bronchodilators. Eligibility time-trends were stud-
ied by dividing the RCTs by start year using three 5-year
periods, and differences were assessed using Kruskal-
Wallis Test.
Results
Inclusion/exclusion criteria reported in RCTs
Using the selection process outlined in Fig. 1, 31 RCTs
were studied (Table 2). These trials, which had start
dates between February 1999 and July 2013, tested three
long-acting muscarinic antagonists (LAMA; tiotropium,
aclidinium and glycopyrronium), three long-acting β-
agonists (LABA; formoterol, indacaterol and olodaterol),
and three LABA/LAMA combinations (indacaterol +
glycopyrronium, vilanterol + umeclidinium and tiotro-
pium + olodaterol). Eighteen trials (58 %) were carried
out in the last 5 years of the study period (2009–2013).
FEV1 was the primary outcome in 29 (94 %) of the trials,
while the remaining two [25, 26] studied reduction of
exacerbation rates.
An overview of RCT eligibility criteria is shown in the
supplement (Additional file 3: Table S8; Additional file 4:
Table S9; Additional file 5: Table S10). Briefly, all trials
included patients aged ≥40 years with a smoking history
of ≥10 pack years. Patients with mild airflow limitation
(%predicted FEV1 ≥ 80), which was found in 19 % of
OPCRD patients, were excluded from all trials. Patients
with severe airflow limitation (%predicted FEV1 < 30),
found in 4 % of patients, were excluded from half of
them, and most trials excluded patients with a recent
history of exacerbations (n = 25). Other frequently ap-
plied COPD-related exclusion criteria included oxygen
treatment (n = 23), recent participation in a pulmonary
rehabilitation program (n = 16) and use of maintenance
oral corticosteroids (n = 12). Finally, all trials excluded
patients with asthma, all but one [27] excluded patients
with concomitant pulmonary disease, and all excluded
patients with other clinically significant diseases using
diverse methodology.
Distribution of reported criteria in the OPCRD population
Using the selection criteria listed in Table 1, 36 893
eligible patients were identified in the OPCRD data-
base (Fig. 2). Demographic and clinical characteris-
tics of this population are shown in Table 3, and the
distribution of other applied criteria is shown in the
supplement (Additional file 6: Tables S11 − S17).
Substantial differences were identified between RCT
participants and patients with COPD in the OPCRD
database. OPCRD patients were on average 7 years older
than RCT participants (71 and 64 years, respectively),
and they were less frequently male (53 % vs 76 %). The
%predicted mean FEV1 was also substantially lower for
RCT participants than for OPCRD patients (49 and
63 %, respectively).
Of the selected OPCRD patients with COPD,
almost half had mMRC score ≥2 [2], 69 % had
recorded prescriptions of maintenance therapy and
50 % had a history of COPD exacerbation within the
past year.
Proportion of OPCRD patients eligible for inclusion in
RCTs
The overall median eligibility of OPCRD patients
with COPD to participate in RCTs was 23 % (IQR
12–38), mean 24 % (range 3.5–58 %, Tables 4, 5 and
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6). Studies of olodaterol [28, 29] showed the highest
eligibility (55 and 58 %), while studies of combin-
ation therapies showed the lowest overall eligibility
(13 %, Table 6), which was primarily due to all but
one [30] being restricted to patients with evidence of
COPD symptoms. As expected, the two studies of
indacaterol + glycopyrronium that focused on redu-
cing exacerbations in a patient population with a
history of exacerbations in the past year [25, 26],
showed the lowest inclusion of 3.5 and 3.9 %,
respectively.
The overall median eligibility (IQR) in the first 5-
year period (1999–2003) was 16 % (10–24 %) when
five RCTs testing tiotropium were carried out. This
rose to 31 % (26–43 %) in the second 5-year period
(2004–2008), when trials of other single therapies
were carried out, and decreased to 18 % (8–38 %) in
the final 5-year period (Fig. 3a). No significant differ-
ence was observed in overall eligibility across the
15-year period (p = 0.076). The relatively high mean
eligibility in 2004–2008 could mainly be attributed
to more relaxed selection criteria for the level of
FEV1 in studies testing single therapies other than
tiotropium (Tables 5 and 6).
A subanalysis of OPCRD patients with more severe
dyspnea (mMRC score ≥2) [2] showed that median eligi-
bility increased from 23 to 27 % (range 4.7–60 %) com-
pared with the overall population (Additional file 6:
Tables S18–S20). A small average increase in eligibility
of 1.0 and 0.6 % was observed for RCTs testing tiotro-
pium or other single therapies respectively, while the
eligibility for RCTs testing combination therapies in-
creased by an average of 7.5 % compared with the over-
all population (Fig. 3b).
Search results from 
ClinicalTrials.gov 
13 October 2014 
 LA-BD treatment tested in COPD patients 
(n=579) 
Spirometry, exacerbations or mortality as 
outcome (n=436) 
Phase 3 or 4 (n=301) 
Randomised double blind placebo controlled 
(n=260) 
 100 participants (n=221) 
Efficacy study with spirometry, exacerbations 
or mortality as primary outcome (n=182) 
Study design / allocation 
o Observational (n=2) 
o Single group (n=9) 
o Non-randomised (n=1) 
o Open label (n=27) 
o Single blind (n=2) 
Primary outcome 
o No spirometry, exacerbations or 
mortality as primary outcome (n=24) 
o Safety measure only (n=15) 
LAMA  or LABA monotherapy /  
LAMA + LABA combination tested (n=52) 
COPD patients in community eligible (n=48) 
Final selection of RCTs with a start date  
before October 2014 (n=31) 
Primary treatment tested 
o ICS + LABA (n=20) 
o ICS withdrawal (n=2) 
o PDE-4 inhibitor (n=3) 
o Triple therapy (n=3) 
Treatment licensed or in process of licensing 
(n=41) 
Selection of specific target patients 
o COPD with >12% reversibility (n=1) 
o Naive to maintenance treatment 
(n=1) 
o Participants of lead-in study (n=1) 
o Using FDC salmeterol /fluticasone  
(n=1) 
Other 
o Twin studies (n=9) 
o Started April 2015 (n=1) 
Duration of treatment 24 weeks (n=80) 
EXCLUDED: 
Fig. 1 Selection of clinical trials. Flow chart showing the criteria and stepwise selection process of eligible randomised controlled trials (RCTs).
Search parameters are outlined in the supplementary methods. Abbreviations: COPD = chronic obstructive pulmonary disease; FDC = fixed-dose
combination; ICS = inhaled corticosteroids; LA-BD = long-acting bronchodilator; LABA = long-acting β-agonist; LAMA = long-acting muscarinic
antagonist; PDE-4 = phosphodiesterase-4; RCT = randomised controlled trial
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Table 2 Selected RCTs, sorted by experimental drug tested, start date and publication date
Generic name drug tested RCT Trial name Sample size Twin studya Start datec Publication date % Male Age
mean ± SD or
median (IQR)
FEV1 % predicted
mean ± SD
Reference
Tiotropium NCT02172287 410 NCT02173691 Feb-99 Jul-02 75 64.9 ± 7.9 Not available [32]
NCT00274014 1010 Oct-00 Mar-06 88 64.8 ± 9.3 35.6 ± 12.6 [27]
NCT00274547 1829 Sep-01 Sep-05 99 67.9 ± 8.6 39.4 ± 13.5 [33]
NCT00277264 913 Jan-02 Nov-07 60 66.9 ± 8.9 39.4 ± 12.0 [34]
NCT00144339 UPLIFT 5993 Dec-02 Oct-08 75 64.5 ± 8.5 45.3 ± 13.6 [12]
NCT00387088 3991 NCT00168844/
NCT00168831
Sep-06 Oct-10 78 64.8 ± 9.1 49.3 ± 13.2 [35]
NCT00563381 POET-COPD 7376 Jan-08 Mar-11 75 62.4 ± 9.0 48.3 ± 13.9 [36]
NCT01126437 17 135 May-10 Oct-13 72 65.0 ± 9.1 47.9 ± 12.7 [37]
NCT01455129b 839 Nov-11 Feb-14 Not available [38]
Formoterol NCT00134979 847 Oct-04 Nov-08 78 62.6 ± 8.9 51.2 ± 13.1 [39]
Aclidinium NCT00363896 ACCLAIM/COPD I 843 NCT00358436 Aug-06 Apr-11 79 62.3 ± 8.3 53.6 ± 15.2 [40]
NCT01001494 ATTAIN 828 Oct-09 Oct-12 67 62.4 ± 8.0 52.5 ± 14.1 [41]
NCT01044459 605 Nov-09 Dec-13 58 63.6 ± 9.7 52.3 ± 13.2 [42]
Indacaterol NCT00463567 1683 Apr-07 Jul-10 63 63.6 ± 9.1 55.6 ± 14.7 [43]
NCT00567996 1002 Nov-07 Jun-11 75 63.6 ± 8.8 53.3 ± 13.9 [44]
NCT00792805 563 Nov-08 Feb-14 94 65.4 ± 8.8 49.9 ± 12.1 [45]
NCT00845728 INVIGORATE 3444 Mar-09 Sep-13 77 64.0 (40–91) 40.5 ± 6.0 [46]
Olodaterol NCT00782210 624 NCT00782509 Nov-08 Jun-14 73 64.9 ± 8.4 48.9 ± 15.4 [28]
NCT00793624 904 NCT00796653 Jan-09 Jul-14 78 63.8 ± 8.7 51.2 ± 14.7 [29]
Glycopyrronium NCT00929110 GLOW2 1066 Jun-09 Nov-12 64 63.7 ± 8.8 56.0 ± 13.3 [47]
NCT01005901 GLOW1 822 Oct-09 Dec-11 82 63.9 ± 9.2 54.5 ± 12.9 [48]
NCT01566604 GLOW7 460 Mar-12 Jan-15 96 64.8 ± 8.1 51.0 ± 12.4 [49]
Indacaterol + Glycopyrronium NCT01120691 SPARK 741 Apr-10 May-13 75 63.3 ± 8.0 37.2 ± 8.1 [25]
NCT01202188 SHINE 2144 Sep-10 Dec-13 75 64.0 ± 8.8 55.2 ± 13.1 [50]
NCT01315249 ILLUMINATE 259 Mar-11 Mar-13 71 63.3 ± 8.0 60.3 ± 10.6 [51]
NCT01709903 LANTERN 676 Nov-12 June-15 91 65.1 ± 7.9 51.8 ± 12.9 [52]
NCT01782326 LANTERN Jul-13 Recruiting [26]
Vilanterol + Umeclidinium NCT01313650 1532 NCT01313637 Mar-11 Oct-13 71 63.0 ± 8.9 47.4 ± 13.1 [53]
NCT01316900 1141 NCT01316913 Mar-11 Jun-14 69 62.9 ± 9.0 47.7 ± 13.0 [54]
NCT01777334 905 Jan-13 Dec-14 68 62.3 ± 8.5 46.4 ± 12.9 [55]
Tiotropium + Olodaterol NCT01431274 2624 NCT01431287 Sep-11 Apr-15 73 64.0 ± 8.3 45.0 ± 11.7 [30]
aA twin study is a RCT registered at ClinicalTrial.gov with identical design, selection criteria and primary outcomes of efficacy. bThis trial was the only one to apply an upper age limit, 85 years. cStart date registered
on ClinicalTrials.gov
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Discussion
Using the selection criteria reported by 31 RCTs and
applying them to a broad UK primary care popula-
tion, this study showed that the overall median eligi-
bility of patients with COPD to participate in RCTs
of inhaled long-acting bronchodilators was 23 % (IQR
12–38). The highest eligibility was identified in two
studies of olodaterol (55 and 58 %). Conversely, the
lowest eligibility was identified in two trials of indaca-
terol + glycopyrronium that required a history of fre-
quent exacerbations (3.5 and 3.9 %). Some variation
was observed in eligibility over time (1999–2013) with
a mean eligibility of 16, 31 and 18 % in the first, sec-
ond and third 5-year periods respectively, although no
significant difference was observed over the whole 15-
year period. A subanalysis of patients with more se-
vere dyspnea (mMRC score ≥2), who would likely be
the patients treated in practice, showed an overall
median eligibility of 27 %.
Five studies have previously investigated the eligibility
of patients with COPD for participation in RCTs of
bronchodilators [16, 19–22]. In agreement with our re-
sults, these studies reported that the majority of commu-
nity patients with COPD would be excluded from RCTs,
although the proportion varied substantially. Our data
agree with the findings by Kruis et al [20] that RCT par-
ticipants are on average younger, more likely to be male,
and have lower %predicted FEV1 compared with the
COPD patient population. Although previous studies
have highlighted important limitations of the generalis-
ability of COPD-related RCTs, they themselves suffer
from substantial limitations that raise questions about
the generalisabilty of their findings. The first is the rep-
resentativeness of the chosen patient population. Four
previous studies considered a low number of patients
(110–696) [16, 19, 21, 22], which likely limits the accur-
acy of their estimates. Of these, two [21, 22] considered
patients from hospital clinics, who likely have more
severe disease on average than patients seen in primary
care. A third study [16] identified patients with COPD in
a postal survey of randomly selected adults in the com-
munity. However, the response rate was low (21 %), and
many of those identified as having COPD had not previ-
ously been diagnosed, which was likely one of the main
reasons for the low reported eligibility. The second im-
portant limitation of previously published studies is the
OPCRD records 
extracted 
n=44 376 
FEV1 recorded 
n=40 759 (91.8%)
mMRC recorded 
n=39 449 (96.8%)
Blood eosinophils 
measured 
n=36 997 (93.8%)
COPD patients 
age 40 years 
n=36 893 (99.7%)
COPD patients 
with mMRC 2 
n=17 075 (46.3%)
Study population 1: 
Total population of 
COPD patients 
Study population 2:  
COPD patients with 
mMRC 2 
Fig. 2 Selection of study population. Patient flow chart showing
selection of study population from the Optimum Patient Care
Research Database (OPCRD). Abbreviations: COPD = chronic
obstructive pulmonary disease; FEV1 = forced expiratory volume in
one second; mMRC =modified Medical Research Council score [2]
Table 3 Characteristics of OPCRD patients with COPD that fulfil
study criteria in Table 1 (n = 36 893)
Characteristic
Age, mean (SD) 71.3 (10.6)
Male, n (%) 19 478 (52.8)
FEV1 % predicted, mean (SD) 62.5 (20.0)
GOLD category of airflow limitation, n (%)
GOLD 1: FEV1≥ 80 % 19.3 % (7 118)
GOLD 2: 50 % ≤ FEV1 < 80 % 53.5 % (19 755)
GOLD 3: 30 % ≤ FEV1 < 50 % 23.0 % (8 468)
GOLD 4: FEV1 < 30 % 4.2 % (1 552)
mMRC score grade ≥2, n (%) 17 075 (46.3)
Pack years of smoking, n (%):
≥ 10 34 758 (94.2)
≥ 20 34 232 (92.8)
Maintenance therapya prescribed within 6 months, n (%) 25 594 (69.4)
Symptomaticb, n (%) 29 579 (80.2)
History of≥ 1 exacerbation in the last year, n (%) 18 373 (49.8)
Abbreviations: COPD chronic obstructive pulmonary disease, FEV1 forced
expiratory volume in 1 s, GOLD Global Initiative for Chronic Obstructive Lung
Disease [2], ICS inhaled corticosteroids, LABA long-acting β-agonists, LAMA
long-acting muscarinic antagonists, LTRA leukotriene receptor antagonists,
mMRC score modified Medical Research Council score [2]
aICS, LAMA, LABA, LTRA or phosphodiesterase inhibitors
bmMRC grade ≥2, or maintenance therapy prescribed within 6 months
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Table 4 Percentagea of total OPCRD patients with COPD eligible for RCTs testing tiotropium (n = 36 893)
Step Criterion for sequential selection NCT02172287 NCT00274014 NCT00274547 NCT00277264 NCT00144339 NCT00387088 NCT00563381 NCT01126437 NCT01455129 Median
1 FEV1 46.8 50.3 46.8 56.3 65.8 46.8 65.8 65.8 72.8 56.3
2 Other inclusion criteria 38.5 20.6 44.5 23.2 54.4 44.5 26.1 55.6 64.7 44.5
3 COPD-related exclusion criteria 37.8 19.9 41.6 21.8 53.4 43.8 25.8 54.4 59.8 41.6
4 Concomitant pulmonary disease 35.6 19.9 41.6 20.2 47.3 41.1 25.5 48.2 52.9 41.1
5 Asthma, allergic diseases and atopy 23.8 14.3 32.9 14.7 37.5 29.8 19.6 38.2 39.1 29.8
6 Comorbidities 16.7 11.2 30.7 9.6 28.8 27.9 15.2 29.3 31.4 27.9
7 Other relevant conditions 15.7 11.2 30.7 9.5 27.1 27.9 14.4 27.5 29.2 27.1
8 Final eligible proportion (%) 15.7 11.2 25.1 9.5 22.5 27.8 11.8 22.9 25.0 22.5
Abbreviations: COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s
aStepwise reduction of the percentage of the total number of OPCRD patients with COPD eligible for individual RCTs (columns) when applying groups of criteria (rows) sequentially. Median values for all RCTs shown in
the table are listed in the last column
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Table 5 Percentagea of OPCRD patients with COPD eligible for RCTs testing other single treatmentsb (n = 36 893)
Step Criterion for sequential selection NCT0013
4979 (Fa)
NCT0036
3896 (Aa)
NCT0100
1494 (A)
NCT0104
4459 (A)
NCT0046
3567 (Ia)
NCT0056
7996 (I)
NCT0079
2805 (I)
NCT0084
5728 (I)
NCT0078
2210 (Oa)
NCT0079
3624 (O)
NCT0092
9110 (Ga)
NCT0100
5901 (G)
NCT0156
6604 (G)
Median
1 FEV1 63.9 80.7 76.5 76.5 76.5 76.5 76.5 23.0 80.7 80.7 76.5 76.5 76.5 76.5
2 Other inclusion criteria 51.4 68.3 64.9 64.9 71.4 72.3 72.3 12.5 76.4 76.4 59.1 72.3 57.8 68.3
3 COPD related exclusion criteria 50.5 67.1 64.3 63.8 57.8 68.8 65.0 10.1 75.6 74.9 56.5 70.2 51.1 64.3
4 Concomitant pulmonary disease 44.8 60.8 58.3 57.9 52.6 62.4 58.3 8.8 74.8 70.9 51.0 62.7 46.2 58.3
5 Asthma, allergic diseases and atopy 34.7 43.8 46.0 45.7 42.0 44.6 46.0 6.8 72.5 66.5 38.0 49.2 34.2 44.6
6 Comorbidities 26.5 42.6 44.7 38.2 32.0 36.0 43.3 6.5 55.0 61.9 28.3 47.8 25.7 38.2
7 Other relevant conditions 26.3 41.5 44.7 38.2 31.7 34.9 43.3 6.5 55.0 57.6 28.1 47.8 25.2 38.2
8 Final eligible proportion (%) 26.3 41.5 44.6 38.1 26.2 34.9 43.3 6.5 55.0 57.6 23.1 39.2 20.7 38.1
Abbreviations: COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s
aStepwise reduction of the percentage of the total number of OPCRD patients with COPD eligible for individual RCTs (columns) when applying groups of criteria (rows) sequentially. Median values for all RCTs shown in
the table are listed in the last column. bOther single treatments include: formoterol (F), aclidinium (A), indacaterol (I), olodaterol (O) or glycopyrronium (G)
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Table 6 Percentagea of total OPCRD patients with COPD eligible for RCTs testing combined treatmentsb (n = 36 893)
Step Criterion for sequential selection NCT01120691
(I + Ga)
NCT01202188
(I + G)
NCT01315249
(I + G)
NCT01709903
(I + G)
NCT01782326
(I + G)
NCT01313650
(V + Ua)
NCT01316913
(V + U)
NCT01777334
(V + U)
NCT01431287
(T + Oa)
Median
1 FEV1 27.2 76.5 67.6 76.5 43.5 65.8 65.8 65.8 80.7 65.8
2 Other inclusion criteria 15.0 59.1 50.2 33.9 13.8 32.9 32.9 32.9 76.4 32.9
3 COPD related exclusion criteria 9.5 42.7 18.4 21.5 10.7 28.5 28.2 31.8 74.9 28.2
4 Concomitant pulmonary disease 8.4 38.2 16.7 19.4 9.4 25.3 25.1 27.8 70.9 25.1
5 Asthma, allergic diseases and atopy 5.4 24.9 11.4 14.9 7.0 20.0 24.4 27.0 68.7 20.0
6 Comorbidities 4.1 19.2 9.0 11.2 5.0 14.8 18.2 20.1 52.2 14.8
7 Other relevant conditions 4.0 18.5 8.9 11.1 4.8 13.7 16.7 18.5 48.9 13.7
8 Final eligible proportion (%) eligible 3.5 15.2 7.2 8.6 3.9 13.7 13.2 14.7 48.9 13.2
Abbreviations: COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s
aStepwise reduction of the percentage of the total number of OPCRD patients with COPD eligible for individual RCTs (columns) when applying groups of criteria (rows) sequentially. Median values for all RCTs shown in
the table are listed in the last column
bCombined treatments include: indacaterol and glycopyrronium (I + G), vilanterol and umeclidinium (V + U), and tiotropium and olodaterol (T + O)
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range of eligibility criteria considered. Four of them
[16, 19–21] considered a limited range of eligibility
criteria. Of these, one [21] only considered criteria
from a single RCT and another [19] did not specify
how the criteria were chosen. Finally, only two previ-
ous studies [16, 20] provided information on eligibility
for participation in individual RCTs.
Compared with the above, the current study has sev-
eral strengths. In the UK all patients are registered with
a General Practitioner (GP) who holds records that in-
clude demographic information, disease and comorbidity
diagnoses as Read codes, prescribing information, test
results, and information related to secondary care visits
and hospitalisations. The OPCRD database is a large UK
community database containing anonymised research-
quality data focused on respiratory disease, derived from
these GP records. Firstly, the database enabled us to as-
sess the eligibility of patients for RCTs in a large and
uniquely representative UK patient population with a
diagnosis of COPD that meets the requirements of the
Quality and Outcomes Framework (QOF), which is the
UK system for the performance management and pay-
ment of general practitioners [31]. The results are there-
fore more likely to be truly representative of community
patients with COPD than previously published studies.
Secondly, we carried out an unbiased and comprehen-
sive search among all trials registered at ClinicalTrials.-
gov and identified 579 studies testing long-acting
Fig. 3 Eligibility to participate in randomised controlled trials (RCT). Eligibility of patients from the Optimum Patient Care Research Database
(OPCRD) to be included in individual randomised controlled trials (RCTs) by RCT start year. Data show fraction of; a total population of patients
with chronic obstructive pulmonary disease (COPD) and b patients with COPD and modified Medical Research Council (mMRC) score
≥2. Data on trials investigating long-acting β-agonists (LABA) are indicated by ○, long-acting muscarinic antagonists (LAMA) by ▲, and
LABA + LAMA combination therapy by ■
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bronchodilators in patients with COPD. From these, we
selected 31 double-blind, placebo-controlled RCTs ac-
cording to pre-specified criteria, extracted all reported
selection criteria and translated them into definitions
compatible with electronic medical records. This re-
sulted in a range of selection criteria that was as close to
the original RCTs as practically possible, which therefore
likely provides better estimates of true eligibility. An
example of this is that, while the study by Kruis et al
[20] considered a large and likely representative COPD
patient population (n = 3 508), the study only applied
common inclusion criteria based on spirometry, smok-
ing status and previous COPD exacerbations, but did
not consider exclusion criteria such as COPD-related
characteristics, the presence of asthma, atopy or other
clinically relevant diseases. In the case of the UPLIFT
trial [12], this resulted in a dramatic difference in eligi-
bility, which was found to be 23 % in our analysis and
42 % in that by Kruis et al. [20] Conversely, Travers et
al. [16] employed similar criteria to our study, but they
also reported potential use of medication as one of the
most common exclusion criteria. The current study did
not exclude people on this basis and, in order to study
the representativeness of the full COPD patient popula-
tion, assumed that all patients would be capable of
undergoing a washout.
Although information for this study was collected
from both ClinicalTrials.gov and published literature, it
is limited by the fact that not all criteria could be com-
pletely translated into definitions that match routine
point-of-care data, and by potentially incomplete report-
ing of criteria in trial protocols. In addition to explicit
selection criteria, clinicians recruiting patients for RCTs
may use their own covert criteria to exclude patients
who are more difficult to manage, are housebound, or
have multiple comorbidities. Furthermore, some real-life
data (eg spirometry) may be less accurately recorded in
primary care than during RCTs. We selected patient re-
cords with a diagnostic Read code for COPD recorded
after April 2008, when a post-bronchodilator FEV1/FVC
<0.70 was introduced as part of the QOF diagnostic pro-
cedure for UK general practitioners and therefore avail-
able in all patients [31]. We also selected records with
complete data on the applied criteria, and patients may
therefore not be fully representative of all patients with
COPD registered in the database. For example, eosino-
phil counts were missing in 7.9 % of extracted records
(6.2 % of records with data on lung function and mMRC
score). Another potential limitation is that exclusion
criteria that refer to recent events (eg exacerbations or
respiratory infections in the past 6 weeks) may be a tem-
porary reason for exclusion that does not permanently
exclude patients from RCT participation. To address
this, we carried out a sensitivity analysis that included
patients that would otherwise have been excluded by
COPD-related criteria in the last 3 months, and found
that this only increased eligibility by 1 %. Finally, this
study focused on the representativeness of the patient
population, but did not study other aspects that cause
RCTs to differ from the real-life ecology of care [5].
Despite these potential limitations, we believe the
current study provides the most comprehensive picture
to date of the eligibility of real-life patients for participa-
tion in RCTs of inhaled long-acting bronchodilators.
Our results show that, overall, around a quarter of com-
munity patients with COPD are eligible for RCT partici-
pation. Some studies represent less than 4 % of patients,
leading to a high risk of “clinician’s fallacy”, while the
most representative studies include over half of the real-
life patient community.
Conclusions
This study combines an extensive range of RCT selection
criteria with a large, representative COPD patient popula-
tion to provide detailed information on eligibility of
patients with COPD for participation in RCTs. The results
highlight that interpretation of outcomes from RCTs of in-
haled long-acting bronchodilators therapy in COPD must
take into account that RCT participants are variably repre-
sentative of real-life patients. In order to assess the rele-
vance of the results of RCTs, it is essential that there is full
and accurate reporting of trial selection criteria in pub-
lished manuscripts and in clinical trial databases. This
analysis also emphasises that, in addition to the results of
RCTs, complementary information from effectiveness
studies of real-life patients with COPD should be an im-
portant consideration for future guideline development.
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